BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 22054177)

  • 21. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
    Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
    Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significant Effects of Renal Function on Mycophenolic Acid Total Clearance in Pediatric Kidney Transplant Recipients with Population Pharmacokinetic Modeling.
    Rong Y; Wichart J; Hamiwka L; Kiang TKL
    Clin Pharmacokinet; 2023 Sep; 62(9):1289-1303. PubMed ID: 37493886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis.
    Wang XX; Liu W; Zheng T; Park JM; Smith DE; Feng MR
    Xenobiotica; 2017 Aug; 47(8):697-704. PubMed ID: 27686146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.
    Ensom MH; Partovi N; Decarie D; Dumont RJ; Fradet G; Levy RD
    Ther Drug Monit; 2002 Apr; 24(2):310-4. PubMed ID: 11897977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic Analysis of Immediate-Release Oral Tacrolimus Co-administered with Mycophenolate Mofetil in Corticosteroid-Free Adult Kidney Transplant Recipients.
    Rong Y; Mayo P; Ensom MHH; Kiang TKL
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):409-422. PubMed ID: 30377942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
    Abd Rahman AN; Tett SE; Staatz CE
    Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
    Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.
    Yu ZC; Zhou PJ; Wang XH; Françoise B; Xu D; Zhang WX; Chen B
    Acta Pharmacol Sin; 2017 Nov; 38(11):1566-1579. PubMed ID: 28836585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis.
    Stuckey L; Clark Ojo T; Park JM; Annesley T; Bartos C; Cibrik DM
    Ther Drug Monit; 2014 Apr; 36(2):148-51. PubMed ID: 24232127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.
    Le Guellec C; Bourgoin H; Büchler M; Le Meur Y; Lebranchu Y; Marquet P; Paintaud G
    Clin Pharmacokinet; 2004; 43(4):253-66. PubMed ID: 15005639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies.
    Saint-Marcoux F; Knoop C; Debord J; Thiry P; Rousseau A; Estenne M; Marquet P
    Clin Pharmacokinet; 2005; 44(12):1317-28. PubMed ID: 16372829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ann Pharmacother; 2006 Sep; 40(9):1509-16. PubMed ID: 16882870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.
    Riglet F; Bertrand J; Barrail-Tran A; Verstuyft C; Michelon H; Benech H; Durrbach A; Furlan V; Barau C
    Drugs R D; 2020 Dec; 20(4):331-342. PubMed ID: 33025511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.